211At-MABG (211At-Meta-Astato-Benzyl-Guanidine) is a norepinephrine transporter (NET) targeting molecule, astatine-211 labeled analogue of 131I-MIBG, developed at the Fukushima University for the treatment of malignant pheochromocytoma and paragangliomas. The indication has the orphan status and only 320 people are diagnosed yearly in Japan with the malignant form. A first Phase I/II clinical trial is under preparation and inclusion has started in 2023. Another trial in 18 patients with pheochromocytomas/paragangliomas has been initiated the same year.
Target/Mechanism: Adrenergic tissues
Radiation Type : Alpha particle (α)